TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged immune cells take on tough lymphoma after transplant
Disease control OngoingThis early-phase trial tests a new approach for patients with aggressive B-cell lymphoma that has come back after treatment. Researchers take a patient's own immune cells (T cells), modify them in the lab to better recognize and kill lymphoma cells, and give them back after a sta…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo shows promise for tough lymphoma
Disease control OngoingThis study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced or returning ly…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New Three-Drug cocktail targets Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the c…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC